Functional Effector Threshold Linked to Response at Limited CAR-T Doses

Company Heidelberg University Hospital Event Type Published Research (Peer-Reviewed, Phase I/II Translational Biomarker Study) Modality Autologous anti-CD19 CAR-T cell therapy (CD28 and 4-1BB costimulatory domains) Asset CD27-negative/CD39-negative functional effector-cell biomarker (research-stage, not a commercial product) Target CD19; biomarker profiling of CD27/CD39 T-cell differentiation and dysfunction…